Aquestive Therapeutics, Inc. (AQST): Price and Financial Metrics


Aquestive Therapeutics, Inc. (AQST): $1.16

0.02 (+1.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AQST POWR Grades

  • Sentiment is the dimension where AQST ranks best; there it ranks ahead of 80.08% of US stocks.
  • The strongest trend for AQST is in Stability, which has been heading down over the past 177 days.
  • AQST ranks lowest in Stability; there it ranks in the 11th percentile.

AQST Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AQST is -0.52 -- better than only 5.4% of US stocks.
  • AQST's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 5.02% of US stocks.
  • The volatility of AQUESTIVE THERAPEUTICS INC's share price is greater than that of 95.34% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to AQUESTIVE THERAPEUTICS INC, a group of peers worth examining would be MYOV, NH, SHPW, ITGR, and RPID.
  • AQST's SEC filings can be seen here. And to visit AQUESTIVE THERAPEUTICS INC's official web site, go to www.aquestive.com.

AQST Valuation Summary

  • AQST's price/sales ratio is 1.2; this is 36.84% lower than that of the median Healthcare stock.
  • AQST's EV/EBIT ratio has moved up 331.5 over the prior 51 months.

Below are key valuation metrics over time for AQST.

Stock Date P/S P/B P/E EV/EBIT
AQST 2022-09-23 1.2 -0.6 -0.8 -2.9
AQST 2022-09-22 1.1 -0.6 -0.8 -2.9
AQST 2022-09-21 1.2 -0.6 -0.8 -2.9
AQST 2022-09-20 1.2 -0.6 -0.8 -2.9
AQST 2022-09-19 1.2 -0.6 -0.8 -2.9
AQST 2022-09-16 1.3 -0.7 -0.9 -3.0

AQST's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AQST has a Quality Grade of C, ranking ahead of 63.9% of graded US stocks.
  • AQST's asset turnover comes in at 0.73 -- ranking 38th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows AQST's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.730 0.693 -0.361
2021-06-30 0.692 0.690 -0.456
2021-03-31 0.808 0.750 -0.415
2020-12-31 0.760 0.717 -0.515
2020-09-30 0.858 0.692 -0.487
2020-06-30 0.929 0.686 -0.524

AQST Price Target

For more insight on analysts targets of AQST, see our AQST price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.20 Average Broker Recommendation 1.4 (Strong Buy)

AQST Stock Price Chart Interactive Chart >

Price chart for AQST

AQST Price/Volume Stats

Current price $1.16 52-week high $6.40
Prev. close $1.14 52-week low $0.62
Day low $1.04 Volume 1,181,600
Day high $1.18 Avg. volume 668,580
50-day MA $1.21 Dividend yield N/A
200-day MA $1.99 Market Cap 61.89M

Aquestive Therapeutics, Inc. (AQST) Company Bio


Aquestive Therapeutics, Inc. operates as a specialty pharmaceutical company that specializes in the drug delivery technology. The company offers PharmFilm, a drug delivery platform/pharmaceutical dosage form that delivers existing prescription products directly to the bloodstream. It develops, manufactures, and commercializes pharmaceutical films, individual film doses, and finished products for patients, physicians, and caregivers. Aquestive Therapeutics, Inc. was formerly known as MonoSol Rx Inc. and changed its name to Aquestive Therapeutics, Inc. in November 2017. The company was founded in 2000 and is based in Warren, New Jersey.


AQST Latest News Stream


Event/Time News Detail
Loading, please wait...

AQST Latest Social Stream


Loading social stream, please wait...

View Full AQST Social Stream

Latest AQST News From Around the Web

Below are the latest news stories about AQUESTIVE THERAPEUTICS INC that investors may wish to consider to help them evaluate AQST as an investment opportunity.

Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board

WARREN, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the establishment of a Scientific Advisory Board comprised of eight allergy experts. “We are very pleased to welcome these leading experts to our Scientific Advisory Board,” said Dan Barber, Chief Executive Officer of Aquestiv

Yahoo | September 12, 2022

JMP Securities Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)

JMP Securities analyst Jason Butler reiterated a Buy rating on Aquestive Therapeutics (AQST - Research Report) today and set a price target of $7.00. The company's shares opened today at $1.42.Butler covers the Healthcare sector, focusing on stocks such as Quoin Pharmaceuticals, Aquestive Therapeutics, and Gamida Cell. According to TipRanks, Butler has an average return of -1.4% and a 43.26% success rate on recommended stocks. Currently, the analyst consensus on Aquestive Therapeutics is a Strong Buy with an average price target of $5.67.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $6.40 and a one-year low of $0.62.

Howard Kim on TipRanks | August 31, 2022

Wedbush Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Aquestive Therapeutics (AQST - Research Report) today and set a price target of $4.00. The company's shares closed today at $1.44.Moussatos covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Aquestive Therapeutics, and Verona Pharma. According to TipRanks, Moussatos has an average return of -7.4% and a 33.23% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aquestive Therapeutics with a $5.67 average price target, representing a 293.75% upside. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $7.

Brian Anderson on TipRanks | August 31, 2022

Aquestive Therapeutics to Participate in Two Investor Conferences in September

WARREN, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the two upcoming investor conferences in September as follows: H.C. Wainwright 24th Annual Global Investment Conference: presentation at 4:00 pm ET on Tuesday, September 13thLake Str

Yahoo | August 31, 2022

Aquestive Therapeutics Receives FDA Tentative Approval for Libervant™ (diazepam) Buccal Film

Libervant provided tentative approval from the FDA for the acute treatment of intermittent, stereotypic episodes of frequent seizure activityLibervant U.S. Market Access currently subject to the expiration of Valtoco® orphan drug market exclusivityCompany hosts conference call at 8:30 am ET on August 31, 2022 WARREN, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards

Yahoo | August 31, 2022

Read More 'AQST' Stories Here

AQST Price Returns

1-mo -14.71%
3-mo 81.31%
6-mo -54.86%
1-year -74.39%
3-year -61.84%
5-year N/A
YTD -70.18%
2021 -27.29%
2020 -8.08%
2019 -7.62%
2018 N/A
2017 N/A

Continue Researching AQST

Want to see what other sources are saying about Aquestive Therapeutics Inc's financials and stock price? Try the links below:

Aquestive Therapeutics Inc (AQST) Stock Price | Nasdaq
Aquestive Therapeutics Inc (AQST) Stock Quote, History and News - Yahoo Finance
Aquestive Therapeutics Inc (AQST) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6192 seconds.